Jan Reiling, PhD, is currently a Principal Scientist at Stablix, Inc., focusing on Discovery & Translational Biology with a specialization in targeted deubiquitination therapeutics. Previously, Jan served as an Institute Research Scientist at UT MD Anderson Cancer Center from 2019 to 2022, and as a Group Leader at the BioMed X Innovation Center from 2013 to 2018, concentrating on cancer metabolism and signaling. Jan also held the position of Associate Principal Scientist at LifeMine Therapeutics from 2022 to 2023. Jan is pursuing a Doctor of Philosophy (Ph.D.) in Molecular Genetics at the University of Zurich.
Location
Cambridge, United States
Links
This person is not in the org chart
This person is not in any teams
This person is not in any offices